Peptide 101: Mazdutide

Mazdutide is a novel dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics (in partnership with Eli Lilly). It is designed to combine the appetite-suppressing and glucose-lowering effects of GLP-1 receptor agonism with the energy expenditure-boosting and lipolytic effects of glucagon receptor agonism. Phase 3 clinical trials have demonstrated significant weight loss, and it received its first approval in China in 2024 for chronic weight management in adults with obesity.

Semaglutide works by telling your body to eat less and absorb food more slowly. Mazdutide does that same thing (GLP-1) but also presses the accelerator on your metabolism (glucagon), telling your body to burn more fat and generate more heat — it's like dieting and boosting your metabolism at the same time.

Mazdutide simultaneously activates two receptors: the GLP-1 receptor, which reduces appetite, slows gastric emptying, and improves insulin secretion; and the glucagon receptor, which promotes hepatic glycogenolysis, increases energy expenditure, and enhances lipolysis (fat breakdown). The glucagon component differentiates mazdutide from pure GLP-1 agonists like semaglutide by adding a thermogenic and fat-mobilizing effect. The dual mechanism aims to produce greater weight loss than GLP-1 agonism alone.

Overall strength of the evidence, by our read: Emerging. Some of what that rests on:

Note, preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and decreased appetite — similar to other GLP-1 receptor agonists but potentially with additional effects from glucagon activation. Transient increases in heart rate have been observed. The glucagon component may cause mild hyperglycemia in some patients, though this is generally offset by the GLP-1 component. Injection site reactions can occur.

Recent research (2026): In a US phase 2 trial, adverse events with mazdutide were mostly gastrointestinal and mild to moderate, but discontinuation due to adverse events was highest in the 16 mg group at 20% (Hsia SH, Bays HE, Billings LK et al., DOI: 10.1016/S2213-8587(26)00160-9).

Reasons to avoid it, or to talk to a clinician first:

This is not a complete safety list. It is the set of things worth knowing before a conversation with a prescriber.

Reviews of physiology, biochemistry and pharmacology · 2027 · glutathione

A review chapter arguing that cancer cells die when the fats in their membranes go rancid. Load a cell with polyunsaturated fats — the omega-3s and omega-6s in fish and seed oils — and they oxidize into lipid peroxides, which are toxic. Tumor cells normally survive this because they carry high levels of GPX4, an enzyme that uses glutathione (the body’s main internal antioxidant) to mop the peroxides up, and the author’s argument is that stripping that defense is what makes radiation, chemo and immunotherapy land. Worth knowing why this one is in your inbox: our tracker caught it on the word “glutathione,” and this is lab-and-theory cancer biology, not a reason to change what you eat or take.

Source ↗

2026-11-15 · INTERVENTIONAL · mazdutide

Everyone talks about fat in the liver. This trial is about fat in the pancreas, which gets far less attention and may matter just as much for how metabolic disease progresses. A hospital in China plans to put 194 adults with overweight or obesity on either mazdutide or a placebo for 48 weeks, everyone on the same diet-and-exercise plan, then measure pancreatic fat directly by MRI rather than inferring it from weight or bloodwork. It has not started recruiting yet and results are not due until mid-2028, so this is a question being asked, not answered.

Source ↗

2026-10-31 · INTERVENTIONAL · survodutide

Weight-loss drug trials have mostly treated menopause as background noise. Boehringer Ingelheim is running this one specifically in women going through or past it — 600 participants in the US, randomized to weekly survodutide (another dual GLP-1/glucagon drug, same two-lever design as mazdutide) or a placebo for 52 weeks. Alongside weight, participants fill out questionnaires about their menopause symptoms and how much those symptoms disrupt daily life, which is the part worth watching: it treats hot flashes and sleep disruption as outcomes rather than footnotes. Recruitment starts at the end of this month and primary results are due in July 2028.

Source ↗

Topics we'll be tracking:

About mazdutide

Mazdutide is not in our regulatory database. It has not been evaluated or approved by the U.S. Food and Drug Administration for any medical use. Discuss with your healthcare provider before considering any substance not reviewed here.

Medical disclaimer

This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.